Veradigm (MDRX) Competitors

Omnicell (NASDAQ:OMCL) and Veradigm (NASDAQ:MDRX) are both small-cap health care technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Which has more volatility & risk, OMCL or MDRX?

Omnicell has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Comparatively, Veradigm has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Does the media refer more to OMCL or MDRX?

In the previous week, Omnicell had 14 more articles in the media than Veradigm. MarketBeat recorded 16 mentions for Omnicell and 2 mentions for Veradigm. Omnicell's average media sentiment score of 0.78 beat Veradigm's score of 0.74 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradigm	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in OMCL or MDRX?

97.7% of Omnicell shares are owned by institutional investors. 2.5% of Omnicell shares are owned by company insiders. Comparatively, 2.3% of Veradigm shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is OMCL or MDRX more profitable?

Omnicell has a net margin of 1.87% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.60% beat Veradigm's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.87%	4.60%	2.56%
Veradigm	N/A	N/A	N/A

Do analysts prefer OMCL or MDRX?

Omnicell currently has a consensus price target of $44.83, indicating a potential upside of 66.79%. Veradigm has a consensus price target of $13.00, indicating a potential upside of 165.31%. Given Veradigm's higher possible upside, analysts clearly believe Veradigm is more favorable than Omnicell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Veradigm	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Which has better earnings & valuation, OMCL or MDRX?

Omnicell has higher earnings, but lower revenue than Veradigm.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.11B	1.13	$12.53M	$0.46	58.43
Veradigm	$1.53B	0.35	N/A	N/A	N/A

Summary

Omnicell beats Veradigm on 10 of the 13 factors compared between the two stocks.